Literature DB >> 21396200

Alternative approaches to tuberculosis treatment evaluation: the role of pragmatic trials.

D J Bratton1, A J Nunn.   

Abstract

Clinical trials are sometimes classified as being explanatory or pragmatic, although they are rarely reported in that way. Explanatory trials may seek to investigate the efficacy of new treatments by imposing strict limitations on many aspects of trial design, including, for example, recruiting only those patients who are most likely to respond. In contrast, the objective of pragmatic trials is to assess whether treatments work in conditions more appropriate to routine practice. This dichotomy is, however, over-simplistic; there is usually a continuum, which is a consequence of there being many areas of trial design that can vary between the extremities of the explanatory and pragmatic approaches. The PRECIS (pragmatic-explanatory continuum indicator summary) wheel based on 10 domains, which include inclusion criteria, flexibility of delivery of the intervention and intensity of follow-up, has been proposed as a way of enabling researchers to assess the extent to which the trials they are designing could be considered explanatory or pragmatic. In this article, we consider how the PRECIS tool can be applied to trials of tuberculosis treatment. In view of the well-recognised delay in getting results from well-conducted clinical trials into practice, we would suggest that if more pragmatic trials were to be conducted, physicians would better understand the implications of the results for their own practice and be more ready to adopt new treatments.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21396200     DOI: 10.5588/ijtld.10.0732

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  7 in total

1.  Rating of Included Trials on the Efficacy-Effectiveness Spectrum: development of a new tool for systematic reviews.

Authors:  L Susan Wieland; Brian M Berman; Douglas G Altman; Jürgen Barth; Lex M Bouter; Christopher R D'Adamo; Klaus Linde; David Moher; C Daniel Mullins; Shaun Treweek; Sean Tunis; Danielle A van der Windt; Merrick Zwarenstein; Claudia Witt
Journal:  J Clin Epidemiol       Date:  2017-02-07       Impact factor: 6.437

2.  How pragmatic or explanatory is the randomized, controlled trial? The application and enhancement of the PRECIS tool to the evaluation of a smoking cessation trial.

Authors:  Peter Selby; Gerald Brosky; Paul I Oh; Vincent Raymond; Suzanne Ranger
Journal:  BMC Med Res Methodol       Date:  2012-07-23       Impact factor: 4.615

3.  The value of the pragmatic-explanatory continuum indicator summary wheel in an ongoing study: the bullous pemphigoid steroids and tetracyclines study.

Authors:  Daniel J Bratton; Andrew J Nunn; Fenella Wojnarowska; Gudula Kirtschig; Anna Sandell; Hywel C Williams
Journal:  Trials       Date:  2012-04-27       Impact factor: 2.279

4.  Impact of Xpert MTB/RIF on Antiretroviral Therapy-Associated Tuberculosis and Mortality: A Pragmatic Randomized Controlled Trial.

Authors:  L Mupfumi; B Makamure; M Chirehwa; T Sagonda; S Zinyowera; P Mason; J Z Metcalfe; R Mutetwa
Journal:  Open Forum Infect Dis       Date:  2014-06-25       Impact factor: 3.835

5.  Pragmatic trials of pain therapies: a systematic review of methods.

Authors:  David Hohenschurz-Schmidt; Bethea A Kleykamp; Jerry Draper-Rodi; Jan Vollert; Jessica Chan; McKenzie Ferguson; Ewan McNicol; Jules Phalip; Scott R Evans; Dennis C Turk; Robert H Dworkin; Andrew S C Rice
Journal:  Pain       Date:  2022-01-01       Impact factor: 6.961

6.  Partnership for fragility bone fracture care provision and prevention program (P4Bones): study protocol for a secondary fracture prevention pragmatic controlled trial.

Authors:  Isabelle Gaboury; Hélène Corriveau; Gilles Boire; François Cabana; Marie-Claude Beaulieu; Pierre Dagenais; Suzanne Gosselin; Earl Bogoch; Marie Rochette; Johanne Filiatrault; Sophie Laforest; Sonia Jean; Alvine Fansi; Diane Theriault; Bernard Burnand
Journal:  Implement Sci       Date:  2013-01-24       Impact factor: 7.327

7.  Making clinical trials more relevant: improving and validating the PRECIS tool for matching trial design decisions to trial purpose.

Authors:  Kirsty Loudon; Merrick Zwarenstein; Frank Sullivan; Peter Donnan; Shaun Treweek
Journal:  Trials       Date:  2013-04-27       Impact factor: 2.279

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.